Article info
Letter
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
- Correspondence to Dr Giacomo Emmi, Department of Experimental and Clinical Medicine, University of Florence, 50134 Firenze, Italy; giacomo.emmi{at}unifi.it
Citation
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
Publication history
- Received May 9, 2022
- Accepted July 8, 2022
- First published July 18, 2022.
Online issue publication
November 10, 2022
Article Versions
- Previous version (18 July 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.